Ucello Therapeutics Funding: $25M Raised, Series A (2022)
Ucello Therapeutics has raised $25M in total funding. Latest round: Series A. Backed by Matrix Partners China, Co-Win Ventures, Northern Light Venture Capital.
Ucello Therapeutics funding overview
Ucello Therapeutics has raised $25M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in February 2022. The round record for Ucello Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include Matrix Partners China, Co-Win Ventures, Northern Light Venture Capital, Elikon Venture, Chengdu Bio-town Fund. 5 distinct backers are named across the disclosed rounds.
Frequently asked about Ucello Therapeutics funding
How much has Ucello Therapeutics raised?
Ucello Therapeutics has raised $25M in total disclosed funding across the rounds on record.
Who has invested in Ucello Therapeutics?
Matrix Partners China, Co-Win Ventures, Northern Light Venture Capital, Elikon Venture, Chengdu Bio-town Fund are named among the investors backing Ucello Therapeutics.
What was the latest Ucello Therapeutics funding round?
The most recent disclosed round is a Series A, announced in February 2022.
Where is Ucello Therapeutics based?
No headquarters location is disclosed for Ucello Therapeutics.
When did Ucello Therapeutics last raise?
The last disclosed Ucello Therapeutics round closed in February 2022 at Series A.
We update the Ucello Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies and their backers are listed below.
